Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated August 19, 2025, titled "Glenmark Pharmaceuticals Inc., USA to launch Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial)".
Press Release Aug 19 2025
Filed with NSE · · 3 pages · English
Summary by 6ix AI
The product is bioequivalent to the reference drug Mycamine and aims to provide affordable alternatives in the market. This announcement highlights Glenmark's commitment to expanding its product portfolio in the institutional channel.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Glenmark Pharmaceuticals Limited on 6ix
Earlier from Glenmark Pharmaceuticals
- Glenmark Pharmaceuticals Inc., USA to launch Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial)
- Press Release Aug 14 2025
- Press Release Jul 10 2025
- Glenmark Launches a Transformative Nutrition and Livelihood Project in Emali, Kenya
- Press Release Jun 24 2025
Later from Glenmark Pharmaceuticals
- Q1FY 2025-26
- FY 2024-25
- Glenmark Pharmaceuticals Inc., USA to launch Eribulin Mesylate Injection, 1mg/2Ml (0.5 mg/mL) Single-Dose Vials
- Press Release Sep 02 2025
- Press Release Sep 05 2025
Follow Glenmark Pharmaceuticals into a list and get an email when it puts out news.
Follow Glenmark Pharmaceuticals